The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have other plans, The Wall Street Journal’s Liz Essley Whyte reports. Hims & Hers Health (HIMS) will keep offering compounded versions of Ozempic and Wegovy tweaked to individual prescriptions, while some pharmacies making the GLP-1 drug copycats will continue, according to the report. Production of pharmacy-prepared versions of Eli Lilly’s (LLY) Zepbound were supposed to have stopped on Wednesday, and later in the spring for knockoffs of Novo Nordisk (NVO) Ozempic and Wegovy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching Barrier
- Hims & Hers price target raised to $22 from $21 at BofA
- Sell Rating for Hims & Hers Health Amid Slowing Core Business Growth and Legal Challenges
- Hims & Hers Health’s (HIMS) App Downloads Surged in February, Says Top Analyst
- FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
Questions or Comments about the article? Write to editor@tipranks.com